EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Expression of the αVβ3 integrin affects prostate cancer sEV cargo and density and promotes sEV pro‐tumorigenic activity in vivo through a GPI‐anchored receptor, NgR2

Cecilia E Verrillo, Fabio Quaglia, Christopher D Shields, Stephen Lin, Andrew V Kossenkov, Hsin-Yao Tang, David Speicher, Nicole M Naranjo, Anna Testa, William K Kelly, Qin Liu, Benjamin Leiby und 6 weitere

Journal of Extracellular Vesicles · 2024

DOI: 10.1002/jev2.12482 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2024. Verfasst von Cecilia E Verrillo und 17 weiteren Autor:innen. Beteiligte Einrichtung: Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Integrin alphaVbeta3, Prostatic Neoplasms, Extracellular Vesicles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NCI NIH HHS, Thomas Jefferson University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It is known that small extracellular vesicles (sEVs) are released from cancer cells and contribute to cancer progression via crosstalk with recipient cells. We have previously reported that sEVs expressing the αVβ3 integrin, a protein upregulated in aggressive neuroendocrine prostate cancer (NEPrCa), contribute to neuroendocrine differentiation (NED) in recipient cells. Here, we examine the impact of αVβ3 expression on sEV protein content, density and function. sEVs used in this study were isolated by iodixanol density gradients and characterized by nanoparticle tracking analysis, immunoblotting and single vesicle analysis. Our proteomic profile of sEVs containing αVβ3 shows downregulation of typical effectors involved in apoptosis and necrosis and an upregulation of tumour cell survival factors compared to control sEVs. We also show that the expression of αVβ3 in sEVs causes a distinct reposition of EV markers (Alix, CD81, CD9) to a low‐density sEV subpopulation. This low‐density reposition is independent of extracellular matrix (ECM) protein interactions with sEVs. This sEV subset contains αVβ3 and an αVβ3 downstream effector, NgR2, a novel marker for NEPrCa. We show that sEVs containing αVβ3 are loaded with higher amounts of NgR2 as compared to sEVs that do not express αVβ3. Mechanistically, we demonstrate that sEVs containing NgR2 do not affect the sEV marker profile, but when injected in vivo intratumorally, they promote tumour growth and induce NED. We show that sEVs expressing NgR2 increase the activation of focal adhesion kinase (FAK), a known promoter of cancer cell proliferation, in recipient cells. We also show that NgR2 mimics the effect of sEVs containing αVβ3 since it displays increased growth of NgR2 transfectants in vivo, as compared to control cells. Overall, our results describe the changes that occur in cargo, density and functions of cancer cell‐derived sEVs containing the αVβ3 integrin and its effector, NgR2, without affecting the sEV tetraspanin profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Integrin alphaVbeta3Prostatic NeoplasmsExtracellular VesiclesMaleHumansAnimalsCell Line, TumorMiceCarcinogenesis

Stichwörter der Autor:innen

NgR2integrinintratumoral injection of small extracellular vesicleslow‐density small extracellular vesiclesneuroendocrine prostate cancersmall extracellular vesicles

Substanzen

Integrin alphaVbeta3

Autor:innen und Institutionen

  • Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Bioinformatics Shared Resource, Center for Systems and Computational Biology, The Wistar Institute, Philadelphia, Pennsylvania, USA.
  • Proteomics and Metabolomics Shared Resource, The Wistar Institute, Philadelphia, Pennsylvania, USA.
  • Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Navneet Dogra, Lucia R Languino

Förderung

  • NIH HHS
  • NCI NIH HHS
  • Thomas Jefferson University
  • Prostate Cancer Foundation
  • NIA NIH HHS
  • Congressionally Directed Medical Research Programs
  • National Institutes of Health

Zitieren

APA

Verrillo, C. E., Quaglia, F., Shields, C. D., Lin, S., Kossenkov, A. V., Tang, H. Y., Speicher, D., Naranjo, N. M., Testa, A., Kelly, W. K., Liu, Q., Leiby, B., Musante, L., Sossey-Alaoui, K., Dogra, N., Chen, T. Y., Altieri, D. C., & Languino, L. R. (2024). Expression of the αVβ3 integrin affects prostate cancer sEV cargo and density and promotes sEV pro‐tumorigenic activity in vivo through a GPI‐anchored receptor, NgR2. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.12482

Vancouver

Verrillo CE, Quaglia F, Shields CD, Lin S, Kossenkov AV, Tang HY, et al. Expression of the αVβ3 integrin affects prostate cancer sEV cargo and density and promotes sEV pro‐tumorigenic activity in vivo through a GPI‐anchored receptor, NgR2. Journal of Extracellular Vesicles. 2024. doi:10.1002/jev2.12482

BibTeX
@article{Verrillo2024,
  author = {Verrillo, Cecilia E and Quaglia, Fabio and Shields, Christopher D and Lin, Stephen and Kossenkov, Andrew V and Tang, Hsin-Yao and Speicher, David and Naranjo, Nicole M and Testa, Anna and Kelly, William K and Liu, Qin and Leiby, Benjamin and Musante, Luca and Sossey-Alaoui, Khalid and Dogra, Navneet and Chen, Tzu-Yi and Altieri, Dario C and Languino, Lucia R},
  title = {Expression of the αVβ3 integrin affects prostate cancer sEV cargo and density and promotes sEV pro‐tumorigenic activity in vivo through a GPI‐anchored receptor, NgR2},
  journal = {Journal of Extracellular Vesicles},
  year = {2024},
  doi = {10.1002/jev2.12482}
}
Kostenlos starten →